Oslo, 22 November 2019: Navamedic ASA (the “Company”) today announces that Lars Hjarrand is appointed Chief Financial Officer of the company effective 9 December, 2019. Hjarrand will join the company on 1 December, 2019 and work together with Toril Marie Ås in the transition period.

Lars Hjarrand has held several executive financial positions and has more than nine years of CFO experience. He has been involved in M&A transactions and has comprehensive experience from both listed and private equity owned companies in different countries and industries. Hjarrand comes from the position as CFO of Lowell Nordics, where he played a central role in the sale of the carve-out business as result of the merger between Intrum Justitia and Lindorff. He held the position as interim CFO of the Lindorff group prior to the merger. He holds an MBA from Carlson School of Management.

 “We are pleased to welcome Lars as our new CFO. Coming with extensive financial and M&A experience, he will play a key role on our journey of building a leading Nordic pharma company. We look forward to working together with Lars in accelerating the growth of Navamedic,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com

About Navamedic ASA: Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.